{"slug":"retatrutide-chemo","verification":{"valid":true,"entries":2,"head":"34034dce22ce2f1521de7ba42763ea12ec8db0a98dbac93e3f3ff6e3bd08636b"},"energy":{"passes":2,"tokens_in":17480,"tokens_out":4119,"tokens_total":21599,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"34034dce22ce2f1521de7ba42763ea12ec8db0a98dbac93e3f3ff6e3bd08636b"},"provenance":[{"ts":"2026-06-30T01:03:29.547Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Retatrutide for Chemo\nSlug: retatrutide-chemo\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"retatrutide\",\"name\":\"Retatrutide\"}],\"drugs_in_scope\":[\"gabapentin-lyrica\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"retatrutide\",\"name\":\"Retatrutide\",\"section_title\":\"Why Retatrutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\",\"**What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\",\"**Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_","response":"{\n  \"slug\": \"retatrutide-chemo\",\n  \"title\": \"Retatrutide for Chemo: Evidence on Metabolic Load, Weight, and Related Signals\",\n  \"body\": \"## What's breaking down\\n\\nChemotherapy can trigger several layers of change. One common layer is shifts in body weight and metabolic state — some regimens promote weight gain through fluid retention, reduced activity, or steroid use, while others lead to loss. Excess weight multiplies compressive forces on the spine, hips, knees, and other structures (roughly 4 lb of lumbar load per extra pound of body weight). Another layer is neuropathic pain signals from nerve irritation, often addressed with medications like gabapentin or pregabalin. A third layer involves systemic inflammation and insulin signaling that may interact with recovery. These layers do not all repair at once; addressing one (such as load) can change the environment for the others. Retatrutide is studied mainly for the metabolic and weight layer. Gabapentin/pregabalin targets the pain-signal layer.\\n\\n## Why Retatrutide might help you\\n\\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. During or after chemo, weight changes can add to this mechanical stress.\\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration or nerve repair.\\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\nHuman data show substantial weight reduction. In Phase 2 trials, participants lost up to 24% body weight at 48 weeks (human|source s22). Phase 3 TRIUMPH-1 results at 80 weeks reached 28.3% average loss at 12 mg, with some reaching 30% at longer follow-up (human|source s4, s0). These changes reduce overall body mass and associated compressive forces.\\n\\nPreclinical work in mouse models of pancreatic, lung, and breast cance","tokens_in":17480,"tokens_out":4119,"cost":0,"prev":"genesis","hash":"f30cc0c3762379285ce9f3b772c4cf0b120725f543b546c05409098193ea65ed"},{"ts":"2026-07-17T02:41:15.243Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-chemo","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f30cc0c3762379285ce9f3b772c4cf0b120725f543b546c05409098193ea65ed","hash":"34034dce22ce2f1521de7ba42763ea12ec8db0a98dbac93e3f3ff6e3bd08636b"}]}